人肺腺癌多药耐药细胞系的建立及其生物学性状的测定

目的：体外建立人肺腺癌细胞多药耐药细胞系。方法：以阿霉素(adriamycin，ADM)为诱导药。人肺腺癌细胞系(SPC-A-1)为诱导对象。逐步增加ADM药物浓度进行诱导，以一定浓度ADM培养46周后．光镜观察细胞形态，采用MTT法检测细胞耐药指数(RF)，并同时对长春地辛、足叶乙甙、顺铂、5-氟脲嘧啶、紫杉醇、ADM6种药物进行交叉耐药检测。结果：SPC-A-1／ADM形态不规则。SPC-A-1／ADM对ADM的RF为11．3．同时对长春地辛、足叶乙甙、顺铂、5-氟脲嘧啶、紫杉醇5种抗癌药物有不同程度的耐药性。结论：建立了相对稳定多药耐药细胞系SPC-A-1／ADM，可用于多药耐药性机制及逆转的研究。

Establishment and detection of the multi-drug resistance of human lung cancer cell line

Objective: To establish the multi-drug resistance of human lung cancer cell line (SPC-A-1/ADM) in vitro. Methods: As doxorubicin was inductive drug, the human lung cancer cell line(SPC-A-1)was gradually added to doxorubicin density. After cultivated for forty-six weeks,we observed the status of the SPC-A-1/ADM. The drug resistance of SPC-A-1/ADM to doxorubicin was detected by MTT assay,and the coefficient drug resistances of it to those of vindesine salphate,etoposide,cisplatin,fluorouracil,paclitaxel were coordinatly detected. Results:The SPC-A-1/ADM was abnormal. As compared with SPC-A-1,the drug resistance of SPC-A-1/ADM to doxorubicin was 11.3 times,and the coefficient drug resistance of it to vindesine salphate,etoposide,cisplatin,fluorouracil,paclitaxel were in different degree. Conclusion:The SPC-A-1/ADM has been established, and it could be used to study the mechanism of multi-drug resistance in future.